

**PRIOR AUTHORIZATION REQUEST FORM
NUEDEXTA®**

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department at 888-509-8142. Failure to submit clinical documentation to support this request will result in delay and/or denial of the request.

If you have prior authorization questions, please call for assistance: Healthy U: 855-856-5694, University of Utah Health Employees: 855-856-5690, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892, MHC 855-885-7695

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:

Height/Weight:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: Nuedexta® (dextromethorphan 20mg and quinidine 10mg)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section.

Questions	Yes	No	Comments/Notes
1. Is the member 18 years of age or older?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Is the requesting provider a neurologist?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Does the member have a documented diagnosis of pseudobulbar affect (PBA) secondary to at least one of the following: <ul style="list-style-type: none"> • Amyotrophic lateral sclerosis • Multiple sclerosis • Ischemic or hemorrhagic stroke • Traumatic brain injury • Dementia – including Alzheimer’s disease, Vascular, Lewy body, or Frontotemporal Dementia 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Has the underlying condition been stable for at least the past 2 months?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
5. Is there documentation of a baseline Center for Neurologic Studies Liability Score (CNS-LS)?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
6. Does the member show clinical symptoms of episodes of sudden uncontrollable and inappropriate laughing or crying?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
7. Is the member’s baseline PBA score \geq 13?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
8. Has the member’s number of PBA episodes per day been documented?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.

9. Has the member had a 3-month trial and failure of, or contraindication to, both of the following medication classes: <ul style="list-style-type: none"> • tricyclic antidepressant (TCA) • selective serotonin reuptake inhibitor (SSRI) 	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
10. Does documentation show a baseline EKG with any significant abnormalities and/or does the member have a history of QT prolongation syndrome?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
REAUTHORIZATION			
1. Is the requesting for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member's therapy been re-evaluated within the past 12 weeks with a neurologist?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Has the requesting provider evaluated for a spontaneous improvement of PBA prior to this renewal request?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Does the requesting prescriber agree to re-evaluate EKG if risk factors change during the course of treatment?	<input type="checkbox"/>	<input type="checkbox"/>	
5. Has the member shown a decrease in CNS-LS score?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
6. Has the member shown at least a 30% improvement in the number of PBA episode per day from baseline?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.			
Additional information:			
Physician Signature:			

****Failure to submit clinical documentation to support this request will result in delay and/or denial of the request****

Policy PHARM- 083
 Origination Date: 09/01/2019
 Reviewed/Revised Date: 10/28/2020
 Next Review Date: 10/28/2021
 Current Effective Date: 11/01/2020

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.